Aimovig 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IAIN/0029/G 
This was an application for a group of variations. 
10/08/2023 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
amended 
on 
Annex II and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0027 
B.II.d.2.d - Change in test procedure for the finished 
22/06/2023 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
II/0026/G 
This was an application for a group of variations. 
15/06/2023 
SmPC 
Update of section 5.1 of the SmPC in order to update 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IB/0025 
B.I.b.2.e - Change in test procedure for AS or 
21/04/2023 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
clinical efficacy and safety information based on final 
results from studies CAMG334A2301 (LIBERTY) and 
CAMG334ADE01 (HER-MES).  
For more information, please refer to the Summary of 
Product Characteristics. 
R/0024 
Renewal of the marketing authorisation. 
15/12/2022 
20/02/2023 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II and PL 
the CHMP considered that the benefit-risk balance of 
Aimovig in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10699
Periodic Safety Update EU Single assessment - 
01/12/2022 
n/a 
PRAC Recommendation - maintenance 
/202205 
erenumab 
IB/0021/G 
This was an application for a group of variations. 
11/07/2022 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IG/1521 
B.II.b.1.a - Replacement or addition of a 
23/06/2022 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0020 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
15/12/2021 
13/06/2022 
SmPC and PL 
life of the finished product - As packaged for sale 
(supported by real time data) 
PSUSA/10699
Periodic Safety Update EU Single assessment - 
02/12/2021 
n/a 
PRAC Recommendation - maintenance 
/202105 
erenumab 
N/0019 
Minor change in labelling or package leaflet not 
28/10/2021 
13/06/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
II/0017 
B.II.d.1.e - Change in the specification parameters 
21/10/2021 
n/a 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
II/0016 
B.II.b.4.c - Change in the batch size (including batch 
22/07/2021 
n/a 
size ranges) of the finished product - The change 
requires assessment of the comparability of a 
biological/immunological medicinal product or a new 
bioequivalence study 
PSUSA/10699
Periodic Safety Update EU Single assessment - 
10/06/2021 
n/a 
PRAC Recommendation - maintenance 
/202011 
erenumab 
II/0013/G 
This was an application for a group of variations. 
06/05/2021 
13/06/2022 
SmPC and PL 
The SmPC section 4.8 has been updated to include rash, 
Update of section 4.8 of the SmPC in line with 
revised clinical safety data. 
Submission of the study report from 5-year open-
label study 20120178 with consequential changes to 
the Section 4.8 and Section 5.1 of the SmPC as well 
as an update of the EU RMP 
Type IA variation to the include ATC code for 
erenumab.  
The Package Leaflet is updated accordingly. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
A.6 - Administrative change - Change in ATC 
oral sores and alopecia. The SmPC and the Risk 
Management Plan has also been updated to reflect the 
results of open-label study 20120178.  
For more information, please refer to the Summary of 
Product Characteristics. 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
Code/ATC Vet Code 
PSUSA/10699
Periodic Safety Update EU Single assessment - 
14/01/2021 
n/a 
PRAC Recommendation - maintenance 
/202005 
erenumab 
IAIN/0014/G 
This was an application for a group of variations. 
23/11/2020 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
PSUSA/10699
Periodic Safety Update EU Single assessment - 
25/06/2020 
25/08/2020 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201911 
erenumab 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10699/201911. 
IAIN/0011 
B.II.b.2.c.1 - Change to importer, batch release 
31/03/2020 
25/08/2020 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IAIN/0010/G 
This was an application for a group of variations. 
31/03/2020 
25/08/2020 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.c.1 - Change to importer, batch release 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0008/G 
This was an application for a group of variations. 
10/03/2020 
n/a 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
PSUSA/10699
Periodic Safety Update EU Single assessment - 
12/12/2019 
13/02/2020 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201905 
erenumab 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10699/201905. 
IB/0007 
B.I.a.1.k - Change in the manufacturer of AS or of a 
29/10/2019 
n/a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
PSUSA/10699
Periodic Safety Update EU Single assessment - 
27/06/2019 
23/08/2019 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201811 
erenumab 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10699/201811. 
II/0003/G 
This was an application for a group of variations. 
25/07/2019 
13/02/2020 
Annex II 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
B.I.b.1.b - Change in the specification parameters 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.II.g.5.c - Implementation of changes foreseen in 
an approved change management protocol - For a 
biological/immunological medicinal product 
IAIN/0005/G 
This was an application for a group of variations. 
28/06/2019 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 7/8 
 
 
 
 
 
 
 
 
 
 
X/0001 
Annex I_2.(c) Change or addition of a new 
28/02/2019 
26/04/2019 
SmPC, 
strength/potency 
Labelling and 
PL 
IAIN/0002/G 
This was an application for a group of variations. 
14/01/2019 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 8/8 
 
 
 
 
 
 
 
 
 
 
 
 
